A policy that would widen pharmacy access to some unapproved peptide injections has gone to the White House, while FDA scientists raise safety concerns.
Recap by typeshit. Full story at Idaho Learning News on MSN.
15:25
Doctor Alex says Ozempic works but comes with a catch, and walks through what he thinks people misunderstand about GLP-1 drugs.
Lilly reports on Oct. 29, and Zacks expects investors to focus on Foundayo after the oral GLP-1 brought in $98 million in its first full quarter on sale.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Experts walk through what peptides are actually used for, what can go wrong with misuse, and how wellness influencers turned them into a social media trend.
Medscape examines how people on GLP-1 medications can be judged both for their weight and for using a drug to treat it.
Loading…